Open AccessThe impact of receptor of advanced glycation end‐products polymorphisms on prostate cancer progression and clinicopathological characteristics
Author(s) -
Chou YingErh,
Hsieh MingJu,
Wang ShianShiang,
Lin ChiaYen,
Chen YenYu,
Ho YungChuan,
Yang ShunFa
Publication year - 2021
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.17025
Subject(s) - prostate cancer , single nucleotide polymorphism , perineural invasion , medicine , oncology , rage (emotion) , genotype , prostate , cancer , glycation , receptor , biology , gene , genetics , neuroscience
The receptor for advanced glycation end products (RAGE) overexpression was suggested to be associated with prostate cancer development and poor prognosis. In this study, we focused on the correlations between the clinicopathological characteristics and susceptibility of prostate cancer and RAGE single‐nucleotide polymorphisms (SNPs). In 579 prostate cancer patients, the RAGE SNPs rs1800625, rs1800624, rs2070600 and rs184003 in patients with or without grade group upgrade were analysed with real‐time polymerase chain reaction. The results demonstrated that the prostate cancer patients who carried the RAGE SNPs rs2070600 ‘GA’ genotypic variants were significantly associated with lower risk to develop grade group upgrade. Moreover, patients with the RAGE rs1800625 ‘TC + CC’ genotypic variants were associated with higher risk of perineural invasion. In 343 prostate cancer patients who carried the RAGE rs1800625 ‘TC + CC’ genotype without grade group upgrade were correlated with higher risk of biochemical recurrence and perineural invasion. In the analysis of TCGA database, significant differences of the RAGE mRNA level were found between the normal controls and prostate cancer patients ( p < 0.0001), and the pathologic stage N1 and N0 patients ( p = 0.0027). The prostate cancer patients with high RAGE expression were associated with lower overall survival rate ( p = 0.025). In conclusion, our results have revealed that the RAGE SNPs rs2070600 and rs1800625 were associated with the grade group upgrade of prostate cancer and clinical status. The RAGE polymorphisms may provide as a pivotal predictor to evaluate prostate cancer disease progression and prognosis.